Bartlett & CO. Wealth Management LLC Sells 1,490 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Bartlett & CO. Wealth Management LLC trimmed its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 48.8% in the 4th quarter, Holdings Channel reports. The fund owned 1,562 shares of the medical equipment provider’s stock after selling 1,490 shares during the quarter. Bartlett & CO. Wealth Management LLC’s holdings in Zimmer Biomet were worth $165,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Equity Investment Corp purchased a new stake in Zimmer Biomet during the 3rd quarter valued at about $70,104,000. Hotchkis & Wiley Capital Management LLC grew its position in Zimmer Biomet by 49.1% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock valued at $189,161,000 after purchasing an additional 577,320 shares during the last quarter. Van ECK Associates Corp grew its position in Zimmer Biomet by 12.4% during the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock valued at $391,239,000 after purchasing an additional 411,163 shares during the last quarter. Thompson Siegel & Walmsley LLC purchased a new stake in Zimmer Biomet during the 3rd quarter valued at about $41,588,000. Finally, D. E. Shaw & Co. Inc. grew its position in Zimmer Biomet by 329.2% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 490,138 shares of the medical equipment provider’s stock valued at $53,195,000 after purchasing an additional 375,929 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Stifel Nicolaus increased their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday. Evercore ISI cut their price objective on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Barclays dropped their price target on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a report on Thursday, December 12th. Royal Bank of Canada raised their price target on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Monday, November 4th. Finally, Wells Fargo & Company raised their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus target price of $124.11.

Zimmer Biomet Price Performance

NYSE ZBH opened at $110.78 on Friday. Zimmer Biomet Holdings, Inc. has a 12 month low of $100.67 and a 12 month high of $133.90. The stock has a market cap of $22.05 billion, a price-to-earnings ratio of 21.06, a PEG ratio of 1.88 and a beta of 1.02. The company’s 50 day moving average is $107.89 and its two-hundred day moving average is $108.09. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.80 billion. During the same quarter last year, the business earned $1.65 EPS. The firm’s revenue was up 4.1% compared to the same quarter last year. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date is Monday, December 30th. Zimmer Biomet’s payout ratio is 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.